Transforming medicine

Acacia Pharma Announces Successful Completion of BARHEMSYS® Post-approval Requirement Study in Patients with Severe Renal Impairment 

Interim Results for the Six Months ended 30 June 2021 - Barhemsys® and Byfavo® Launches Continue to Achieve Strong Hospital Formulary Adoption

Acacia Pharma Announces Submission and Validation of Marketing Authorization Application for BARHEMSYS® (amisulpride injection) in Major European Markets

Acacia Pharma Announces Initiation of Pivotal Study of Byfavo® in Pediatric Procedural Sedation

Acacia Pharma to Host Webinar with Key Opinion Leaders to Discuss the Hospital User Experience with Barhemsys® and Byfavo®

Acacia Pharma Announces Significant Continued Progress with Formulary Uptake of BARHEMSYS® and BYFAVO™ in the US

Results of Annual General Meeting

Acacia Pharma to Participate in Jefferies Virtual Healthcare Conference

Acacia Pharma Appoints Debra Hussain as Chief Commercial Officer

Acacia Pharma Announces Early Repayment of Loan Facility from Hercules Technology Growth Capital

Acacia Pharma Becomes New Industry Supporter of the American Society of Anesthesiologists

Publication of Annual Report and Financial Statements for the Year ended 31 December 2020

Results for the Year ended 31 December 2020

Change of EU Home Member State

Acacia Pharma Launches BYFAVO™ (remimazolam) in the United States for Procedural Sedation in Adults Undergoing Medical Procedures Lasting 
30 Minutes or Less

Acacia Pharma Wins BEL Small Company of the Year for the Second Consecutive Year